Twelve-year-old Ugandan soccer star and malaria survivor Charles Ssali, together with Major League Soccer Commissioner Don Garber, is making a stop in New York today to formally launch the United Against Malaria campaign in the United States. Starting with a breakfast event in Times Square, Ssali will be welcomed to the United Nations by avid soccer fan, Deputy Secretary-General Dr. Asha-Rose Migiro.This initiative is a partnership that aims to harness the popularity of soccer and the excitement leading up to the 2010 FIFA World Cup South AfricaTM as a way to raise global awareness and build worldwide commitment to ending malaria, as well as increase the use of prevention tools and malaria treatment in Africa.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/thegatesfoundation/41028/
After a successful pilot program in October 2009, Cancer Treatment Centers of America (CTCA) is introducing an innovative approach to cancer treatment this July at each of its four hospitals in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Called “Patient Empowered CareSM,” this advancement in the patient treatment delivery process offers patients an average of between two and three hours with a dedicated team of specialized oncology physicians and clinicians.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancercenter/44523/
Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market and manufacturer of the industry's three premier brands: Thermage®, Fraxel®, and Isolaz®, is pleased to announce that it has partnered with PGA TOUR golfer Scott McCarron to raise awareness about skin protection and the Fraxel re:store® laser treatment. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin, including the removal of actinic keratoses (AK’s ) — a precancerous skin condition caused by sun exposure. Fraxel re:store treatment provides superior results for AKs on the face or other areas of the body displaying the signs of photodamage.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/solta/45388/
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
Close-Up TV News recognizes the Orthopaedic & Spine Institute for its remarkable commitment to quality care, providing relief to thousands of patients.
Spine surgery has advanced significantly over the past decade, allowing for more reliable outcomes, less surgical morbidity and quicker recovery. Dr Steven Cyr of the Orthopaedic & Spine Institute in San Antonio (http://www.saspine.com) offers some of the country’s most advanced training, compassionate care and individualized treatment options to help eliminate back and neck pain and improve his patients’ quality of life.
To view MultiMedia News Release, go to http://multivu.prnewswire.com/mnr/closeuptvnews/46410/
A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or ‘bird flu,’ even when given late in the course of illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/outcome/46648/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
Two of the most advanced tools for precise, radiotherapy-based treatment are now under one roof in Seattle. Swedish Medical Center this month became the first facility in the Pacific Northwest – and one of only a handful in North America – to open a unit that incorporates both CyberKnife and Gamma Knife technologies. The 3,950-square-foot Swedish Radiosurgery Center, formerly known as the Seattle CyberKnife Center, is located on the
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
As many as one in five U.S. teens suffers from disabling mental illness. Throughout Mental Health Awareness Month in May, BeSmartBeWell.com highlights the issue of mental illness in teens and tells the stories of two teens who moved from diagnosis through treatment and recovery.
What does mental illness look like in teens? It looks like Colleen, who’s battled depression and anxiety since she was 13, and Katie, who struggled with addiction in her early teens. Mental illness in teens looks just like the kid next door – studies show nearly half of all youth will experience a mental disorder at some point in their lives.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50033/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
